Literature DB >> 21323569

Near eradication of clinically relevant concentrations of human tumor cells by interferon-activated monocytes in vitro.

Samuel Baron1, Joel Finbloom, Julie Horowitz, Joseph Bekisz, Angel Morrow, Tongmao Zhao, Samuel Fey, Hana Schmeisser, Corey Balinsky, Kotaro Miyake, Christopher Clark, Kathryn Zoon.   

Abstract

We have previously reported that low concentrations of interferon (IFN)-activated monocytes exert near-eradicative cytocidal activity against low concentrations of several human tumor cells in vitro. In the present study, we examined 7 human tumor cell lines and 3 diploid lines in the presence or absence of 10 ng/mL IFNα2a and monocytes. The results confirmed strong cytocidal activity against 4 of 7 tumor lines but none against 3 diploid lines. To model larger in vivo tumors, we increased the target cell concentration and determined the concentration of IFNα2a and monocytes, required for cell death. We found that increasing the tumor cell concentration from 10- to 100-fold (10(5) cells/well) required an increase in the concentration of IFNs by over 100-fold and monocytes by 10-fold. High concentrations of monocytes could sometimes kill tumor or diploid cells in the absence of IFN. We may conclude that killing of high concentrations of tumor or diploid cells required high concentrations of monocytes that could sometimes kill in the absence of IFN. Thus, high concentrations of tumor cells required high concentrations of IFN and monocytes to cause near eradication of tumor cells. These findings may have clinical implications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21323569      PMCID: PMC3128785          DOI: 10.1089/jir.2010.0153

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  34 in total

Review 1.  Molecular mechanisms for activated macrophage recognition of tumor cells.

Authors:  C C Pak; I J Fidler
Journal:  Semin Cancer Biol       Date:  1991-06       Impact factor: 15.707

2.  IRF9 is a key factor for eliciting the antiproliferative activity of IFN-alpha.

Authors:  Takaya Tsuno; Josef Mejido; Tongmao Zhao; Hana Schmeisser; Angel Morrow; Kathryn C Zoon
Journal:  J Immunother       Date:  2009-10       Impact factor: 4.456

Review 3.  Reversal of tumor-induced immunosuppression: a new approach to cancer therapy.

Authors:  S Wojtowicz-Praga
Journal:  J Immunother       Date:  1997-05       Impact factor: 4.456

4.  Impaired oxidative burst does not affect human monocyte tumoricidal activity.

Authors:  A R Chen; H S Koren
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

5.  Clinical model: interferons activate human monocytes to an eradicative tumor cell level in vitro.

Authors:  Samuel Baron; Jessica Hernandez; Joseph Bekisz; Joyce Poast; Neil Goldman; Kathleen Clouse; Karen Fields; Sylvia Bacot; Jiun Wang; Kathryn Zoon
Journal:  J Interferon Cytokine Res       Date:  2007-02       Impact factor: 2.607

Review 6.  Human interferons alpha, beta and omega.

Authors:  Joseph Bekisz; Hana Schmeisser; Jessica Hernandez; Neil D Goldman; Kathryn C Zoon
Journal:  Growth Factors       Date:  2004-12       Impact factor: 2.511

Review 7.  What's new in macrophage-tumor cell interaction?

Authors:  L Kopper; K Lapis
Journal:  Pathol Res Pract       Date:  1985-05       Impact factor: 3.250

8.  Tumor-derived monocyte chemoattractant protein-1 induces intratumoral infiltration of monocyte-derived macrophage subpopulation in transplanted rat tumors.

Authors:  S Yamashiro; M Takeya; T Nishi; J Kuratsu; T Yoshimura; Y Ushio; K Takahashi
Journal:  Am J Pathol       Date:  1994-10       Impact factor: 4.307

9.  Distinct mechanisms are involved in tumoristatic and tumoricidal activities of monocyte-derived dendritic cells.

Authors:  Nathalie Vanderheyde; Peter Vandenabeele; Michel Goldman; Fabienne Willems
Journal:  Immunol Lett       Date:  2004-02-15       Impact factor: 3.685

10.  How does interferon inhibit tumour growth?

Authors:  I Gresser
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1982-09-24       Impact factor: 6.237

View more
  10 in total

1.  Apoptosis-inducing factor (AIF) is targeted in IFN-α2a-induced Bid-mediated apoptosis through Bak activation in ovarian cancer cells.

Authors:  Kotaro Miyake; Joseph Bekisz; Tongmao Zhao; Christopher R Clark; Kathryn C Zoon
Journal:  Biochim Biophys Acta       Date:  2012-06-07

2.  Human monocytes in the presence of interferons alpha2a and gamma are potent killers of serous ovarian cancer cell lines in combination with paclitaxel and carboplatin.

Authors:  Chase L Johnson; Daniel S Green; Kathryn C Zoon
Journal:  J Interferon Cytokine Res       Date:  2014-07-28       Impact factor: 2.607

3.  Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors.

Authors:  Hideyuki Nakashima; Kotaro Miyake; Christopher R Clark; Joseph Bekisz; Joel Finbloom; Syed R Husain; Samuel Baron; Raj K Puri; Kathryn C Zoon
Journal:  Cancer Immunol Immunother       Date:  2011-12-13       Impact factor: 6.968

4.  Type I Interferon-Mediated Induction of Antiviral Genes and Proteins Fails to Protect Cells from the Cytopathic Effects of Sendai Virus Infection.

Authors:  Jacquelyn R Bedsaul; Luna A Zaritsky; Kathryn C Zoon
Journal:  J Interferon Cytokine Res       Date:  2016-08-10       Impact factor: 2.607

5.  Monocyte and interferon based therapy for the treatment of ovarian cancer.

Authors:  Daniel S Green; Ana T Nunes; Christina M Annunziata; Kathryn C Zoon
Journal:  Cytokine Growth Factor Rev       Date:  2016-03-15       Impact factor: 7.638

Review 6.  Immunomodulatory effects of interferons in malignancies.

Authors:  Joseph Bekisz; Yuki Sato; Chase Johnson; Syed R Husain; Raj K Puri; Kathryn C Zoon
Journal:  J Interferon Cytokine Res       Date:  2013-04       Impact factor: 2.607

7.  Combination immunotherapy with IL-4 Pseudomonas exotoxin and IFN-α and IFN-γ mediate antitumor effects in vitro and in a mouse model of human ovarian cancer.

Authors:  Daniel S Green; Syed R Husain; Chase L Johnson; Yuki Sato; Jing Han; Bharat Joshi; Stephen M Hewitt; Raj K Puri; Kathryn C Zoon
Journal:  Immunotherapy       Date:  2019-04       Impact factor: 4.040

8.  Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.

Authors:  S Karakhanova; E Ryschich; B Mosl; S Harig; D Jäger; J Schmidt; W Hartwig; J Werner; A V Bazhin
Journal:  Br J Cancer       Date:  2015-03-17       Impact factor: 7.640

Review 9.  Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points.

Authors:  Janina Świderska; Mateusz Kozłowski; Sebastian Kwiatkowski; Aneta Cymbaluk-Płoska
Journal:  Cancers (Basel)       Date:  2021-12-01       Impact factor: 6.639

10.  A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer.

Authors:  Daniel S Green; Ana T Nunes; Virginia David-Ocampo; Irene B Ekwede; Nicole D Houston; Steven L Highfill; Hanh Khuu; David F Stroncek; Seth M Steinberg; Kathryn C Zoon; Christina M Annunziata
Journal:  J Transl Med       Date:  2018-07-16       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.